Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceutical giant Bristol-Myers Squibb (NYSE: BMY) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Bristol-Myers' business and see what CAPS investors are saying about the stock right now.

Bristol-Myers facts

Headquarters (founded)

New York (1887)

Market Cap

$47.6 billion

Industry

Pharmaceuticals

Trailing-12-Month Revenue

$19.7 billion

Management

CEO Lamberto Andreotti

CFO Charles Bancroft

Return on Equity (average, past 3 years)

31.5%

Cash/Debt

$6.8 billion / $5.4 billion

Dividend Yield

4.7%

Competitors

AstraZeneca (NYSE: AZN)

Merck (NYSE: MRK)

Pfizer (NYSE: PFE)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 94% of the 1,675 members who have rated Bristol-Myers believe the stock will outperform the S&P 500 going forward. These bulls include All-Star healthcarevalue, who is ranked in the top 5% of our community, and tbonci.

A couple of months ago , healthcarevalue listed several of Bristol-Myers' positives:

Low debt/equity. ... Reasonable price/earnings, which is low for historic levels of BMY. Market cap ... leaves some room to grow, but also indicates stability. However, the most single impressive track record of BMY is its historic positive and impressive values for Return on Invested Capital.

In fact, Bristol-Myers boasts a robust three-year average ROIC of roughly 30%. That's higher than rivals AstraZeneca (25%), Merck (20%), and Pfizer (8%).

CAPS member tbonci elaborates on the Bristol-Myers bull case:

BMY is in a solid business position. Their drug portfolio is wide-ranging and covers cardiovascular, HIV, cancer, and neuropathy. Their products (such as Plavix and Abilify) are well accepted by the Health Care industry and prescribed regularly. Looking forward, a new cancer drug was just approved in Europe, and many more drugs are in trials, including more promising cancer treatments.

What do you think about Bristol-Myers, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Pfizer. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.